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Abstract
Background Few investigations have been conducted that compared blood glucose in patients with diabetes mellitus (DM2) and
morbid obesity who had undergone laparoscopic sleeve gastrectomy (LSG) or gastric bypass (LRYGB). We aimed to compare
the effects of these procedures using continuous glucose monitoring (CGM).
Methods We prospectively studied patients that had qualified for LSG or LRYGB. The inclusion criteria were DM2 of ≤ 5 years,
for which patients were taking oral anti-diabetic drugs, or no glucose metabolism disorder; and morbid obesity. CGM was
performed between admission and the 10th postoperative day.
Results We studied 16 patients with DM2 and 16 without. Eighteen patients underwent LSG and 14 underwent LRYGB. The
median hemoglobin A1c was 5.5% (5.4–5.9%) in DM2 patients, which did not differ from control (p = 0.460). Preoperativemean
daily glucose concentration was similar between DM2 and control patients (p = 0.622). For patients with DM2, LRYGB was
associatedwithmore frequent low glucose status, and these episodes lasted longer than in DM2 patients that underwent LSG (p =
0.035 and 0.049, respectively). DM2 patients that underwent LRYGB demonstrated lower glucose concentrations from third
postoperative day than those that underwent LSG. Patients without DM2 did not demonstrate differences in daily mean glucose
concentrations, or in incidence nor duration of hypoglycemia throughout the observation period.
Conclusion A significantly larger reduction in interstitial glucose concentration is present from third day in patients with DM2
who undergo LRYGB vs. LSG, accompanied by a lower incidence and shorter duration of low glucose episodes.
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Introduction
Improvements in control or complete resolution of obesity-
related comorbidities are observed after various types of bar-
iatric surgery. Previously published studies and recommenda-
tions have classified these types of surgery according to their
effects on metabolism, and have concluded that laparoscopic
Roux-en-Y gastric bypass (LRYGB) can be more beneficial
than laparoscopic sleeve gastrectomy (LSG) for the treatment
of type 2 diabetes mellitus (DM2), remission of other obesity-
related comorbidities, and weight loss [1–4]. However, a lit-
erature search revealed that the changes in glucose concentra-
tion in patients with DM2 and morbid obesity in the periop-
erative period had not been thoroughly compared between
LSG and LRYGB. Some previous studies have reported com-
parable efficacy of LSG and LRYGB in long-term treatment
of DM2 [5]. However, we hypothesized that daily glycemic
excursions in morbidly obese patients after LRYGB would
differ significantly from those following LSG.
A comprehensive record of the changes in glucose homeo-
stasis can be achieved by continuous glucose monitoring
(CGM), which permits recording of 288 data points every
24 h. We therefore aimed to use this to monitor interstitial
glucose concentrations in the perioperative period for patients
who were undergoing bariatric surgery.
Materials and Methods
Study Design
A prospective observational study was performed using data
derived from the anamnesis, physical examination, and the
results of CGM, of consecutive patients in a tertiary academic
referral surgical center.
Inclusion criteria:
& Patients aged 18–65 years;
& Patients with a body mass index (BMI) of 35–50 kg/m2;
& Patients qualified for bariatric procedures (LSG or
LRYGB) according to the Polish Guidelines for Bariatric
and Metabolic Surgery [6, 7];
& Patients who had been diagnosed with DM2 at least
6 months prior to the surgery, but who had had the disease
for ≤ 5 years, and who were taking oral anti-diabetic med-
ications (≤ 4), but not insulin (the DM2 group); OR an
absence of diabetes mellitus (the control group);
Exclusion criteria:
& Patients with complications following diabetes mellitus
(diabetic nephropathy, diabetic retinopathy, diabetic
neuropathy, or diabetic foot ulcers), type 1 diabetes, sec-
ondary diabetes, chronic pancreatitis, or oral steroid
therapy;
& Patients undergoing a revision procedure;
& Patients with a diagnosis of mental illness that would im-
pede cooperation;
& Alcohol or drug abuse;
Study phases:
1. Preparation and preoperative clinical assessment: in-
formed consent, full clinical examination, measurement
of bodymass, calculation of BMI, and baseline evaluation
of biochemical parameters (including fasting glucose and
hemoglobin A1c [HbA1c]). Patients were divided in two
groups on the basis of the procedure performed (LSG or
LRYGB), with subgroups of individuals defined by the
presence or absence of DM2.
2. Perioperative CGM using a FreeStyle Libre system: con-
tinuous monitoring of interstitial glucose concentration in
the patients’ subcutaneous tissue. Preoperative mean daily
glucose concentration was measured from the day prior to
surgery starting at 8–9 am, up to the beginning of anes-
thesia (24 h, labeled as Bday 1 of CGM^). Then, the mea-
surement labeled as Bday 2 of CGM^ started. For 10 con-
secutive days, CGM was performed. Patients were
discharged from hospital at day 3, since admission (post-
operative day 2) and CGM was continued in patients’
homes.
3. Devices were returned after completing 10 days of CGM,
during follow-up visits. Adverse events were recorded at
this time.
A study flow diagram is presented as Fig. 1.
Treatment Protocol
Patients were treated in accordance with the Enhanced
Recovery after Surgery (ERAS) protocol, with regard to pre-
operative, intraoperative, and postoperative interventions [6,
8–10]. During the preoperative period, patients were appro-
priately counseled and thoroughly examined, with particular
emphasis on the presence and management of DM2 and any
significant comorbidities. Preoperatively, patients were sched-
uled for educational meetings, visits with the dietician, who is
teaching them what and how to eat postoperatively. Patients’
diets were standardized during hospital stay. On admission
day, a normocaloric diet was administered. Fasting time was
started 6 h before anesthesia, while clear liquids were accept-
able up to 2 h before. On the operation day, intravenous glu-
cose and insulin were administered by anesthesiologist, if nec-
essary. Postoperatively, patient was encouraged to drink clear
liquids. If tolerated, patients were given yoghurt and high
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protein drinks in the evening. From the day after operation,
patients were advanced to liquid diet, then received strict die-
tary recommendations to stay on liquid diet for the first month
postoperatively. Postoperatively, patients were not on oral
anti-diabetic medications. Then, in the first month, they had
a follow-up visit with diabetologist, who was administering
anti-diabetic medications if necessary (based on glucose pro-
file done based on glucose finger prick testing). All patients
were scheduled to have at least three follow-up appointments:
2 weeks, 1 month, and 3 months after discharge.
Surgical Techniques
The surgical techniques for LSG and LRYGB were standard-
ized and have been described in previous publications [9, 11,
12]. Sleeve gastrectomy was commenced 4–5 cm proximal to
the pylorus, followed by 38 F bougie trimming. During
LRYGB, a pouch was formed using three 45-mm staplers
(one horizontal and two vertical) and a gastrojejunal anasto-
mosis was created using a linear stapler. The length of the
Roux and biliopancreatic limbs was standardized to be up to
150 and 100 cm, respectively.
Continuous Glucose Monitoring Technique
The Freestyle Libre CGM is used for the continuous mea-
surement of glucose concentration in the interstitial fluid
(ISF) of subcutaneous tissue for up to 14 days. It is
coupled with a sensor, which consists of a thin needle
placed in the subcutaneous tissue on the posterior surface
of the arm. If the patients were not able to reach the
posterior surface of their arm, the sensor was allowed to
be placed at anterior facet of abdominal wall, however
none required that placement. Glucose oxidase, at the
end of needle in subcutaneous tissue, catalyzes the glu-
cose oxidation reaction that causes electrons to be trans-
ferred to a thin sensor needle. The resulting electric
current is registered by the sensor and converted by the
Freestyle Libre CGM into glucose concentration. The
measurements are automatically saved on the device and
can be synchronized and downloaded to a computer. The
device is a wireless system and its use does not require
additional training of the patient. Freestyle Libre CGM
Software was used to analyze daily glycemic trends. The
measurement error does not exceed 10% [13–16] and the
system was validated for use in the operating room and
intensive care unit [17]. The subcutaneous tissue com-
prises of interstitial fluid, which contains glucose
transported from blood capillaries by simple diffusion
[18]. The glucose concentration in the ISF closely follows
blood glycemia, however with a slight time delay (be-
tween 5 and 10 min in different studies) [19]. For com-
pensation in CGM devices, complex algorithms are
employed, which can adjust for rapid changes of glycemia
and time delays, resulting in more accurate glucose mea-
surements for the end user [14, 20, 21].
Outcomes
The primary outcome was to record the fluctuation in intersti-
tial glucose concentration each day in patients undergoing
LSG or LRYGB.
Statistical Analysis
Comparisons of baseline patient data were conducted using
Student’s t test or the Mann-Whitney U test for quantitative
variables, and the chi-square test, with or without Yates’s cor-
rection, for qualitative variables. All repeated measurements
were analyzed with MANOVA or Friedman ANOVA, with
post hoc analyses. Results were considered significant with
p value < 0.05. Data were analyzed using Statistica version
13.0 PL (StatSoft Inc., Tulsa, OK, USA).
Assessed for eligibility (n=50)
Exluded (n=18)
Not meeting inclusion criteria (n=16)
Declined to participate (n=2)
LRYGB group (n=14)LSG group (n=18) Operation
Included (n=32)
Enrollment
Analysis for 10 
consecutive days
T2DM (n=6) Control (n=12) T2DM (n=10) Control (n=4)
Fig. 1 Flowchart
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Results
Characteristics of the Study Group
We enrolled 32 patients undergoing surgery in the 2nd
Department of General Surgery, Jagiellonian University
Medical College. There were 12 men and 20 women, with a
mean age of 43 ± 10 years. Eighteen patients underwent LSG
(10 men and 8 women), while 14 underwent LRYGB (2 men
and 12 women).
The baseline characteristics of patients with and without
DM2, who qualified for bariatric procedures, are presented
in Table 1. Patients with DM2 were mostly assigned to
LRYGB (62.5 vs. 25%). There were no differences in sex
distribution between the DM2 and control groups. However,
patients with DM2were significantly older than controls [46.5
(40–58.5) vs. 39 (30–44.5)]. Comorbidity index, assessed
using American Society of Anesthesiologists class (ASA
class), was higher in DM2 patients, reflecting higher preva-
lence of arterial hypertension, coronary and peripheral vascu-
lar disease, and obstructive sleep apnea. The preoperative met-
abolic panel was comparable in the DM2 patients and control
group. In the group of patients assigned to LSG, most were
male (56%), while the opposite was true for those assigned to
LRYGB (14%) (p = 0.020; subsequent ANOVA analyses
were standardized with regard to sex). Age did not differ
among the surgical subgroups, and neither did maximal pre-
operative BMI, nor BMI on admission to hospital. Themedian
duration of DM2 was 2.5 (1.5–3.5) years, with no significant
difference between the type of procedure undergone (p =
0.062). Fourteen patients were being treated with metformin
(eight patients with prolonged-release tablets at 1000 mg/dose
and six patients with coated tablets at doses of 500 or 850 mg,
with the appropriate daily dose having been determined by a
diabetes specialist) and two were being treated with gliclazide
(prolonged-release tablets; 30 mg daily). The patients’ DM2
was well-controlled by their oral medication, which was
reflected in a median HbA1c concentration of 5.5% (5.4–
5.9%). The median HbA1c in non-diabetic individuals was
5.3% (5.2–5.4%; p = 0.460). Preoperative mean daily non-
fasting glucose concentrations did not differ between patients
with DM2 and those without (p = 0.622).
Main Outcomes
The median postoperative glucose concentration over the en-
tire study was 4.6 (4.1–5.2) mmol/L and did not differ be-
tween the groups [LSG vs. LRYGB, p = 0.426; DM2 vs.
Table 1 Basic groups characteristics
DM2 Control P value
n (%) 16 (50%) 16 (50%) n/a
LSG/LRYGB, n (%) 6/10 (37.5%/62.5%) 12/4 (75%/25%) 0.037
Males/females, n (%) 6/10 (37.5%/62.5%) 6/10 (37.5%/62.5%) 0.642
Median age, years (IQR) 46.5 (40–58.5) 39 (30–44.5) 0.005
Median maximal preoperative BMI, kg/m2 (IQR) 46.69 (41.43–48.63) 46.44 (43.06–48.51) 0.895
Median BMI on admission, kg/m2 (IQR) 43.99 (38.92–47.19) 43.82 (39.92–45.68) 0.895
Comorbidities:
ASA class 2, n (%) 10 (62.5%) 16 (100%) n/a
ASA class 3, n (%) 6 (37.5%) 0
Non-alcoholic steatohepatitis, n (%) 0 4 (25%) n/a
Arterial hypertension, n (%) 12 (75%) 6 (37.5%) 0.037
Coronary vascular disease, n (%) 2 (12.5%) 0 n/a
Peripheral vascular disease, n (%) 4 (25%) 0 n/a
Obstructive Sleep Apnea, n (%) 8 (50%) 2 (12.5%) 0.027
Tobacco smoking, n (%) 0 0 n/a
Metabolic panel:
Median HbA1c, % (IQR) 5.5 (5.4–5.9) 5.3 (5.2–5.4) 0.086
Median triglycerides, mmol/L (IQR) 1.76 (1.09–2.27) 1.52 (1.1–1.85) 0.364
Median HDL, mmol/L (IQR) 1.2 (0.98–1.49) 1.14 (0.79–1.19) 0.275
Median LDL, mmol/L (IQR) 2.86 (2.32–3.22) 3.03 (2.48–3.56) 0.415
Median total cholesterol, mmol/L (IQR) 4.65 (4–5) 4.5 (4–4.8) 0.870
Preoperative, mean daily glucose concentration, mmol/L ± SD 4.3 ± 1.1 4.1 ± 1.2 0.622
LSG laparoscopic sleeve gastrectomy, LRYGB laparoscopic gastric bypass, BMI body mass index, ASA American Society of Anesthesiologists classi-
fication, HbA1c glycated hemoglobin A1, HDL high-density lipoproteins, LDL low-density lipoproteins
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control, p = 0.469 (standardized for differences in sex distri-
bution)]. In all 32 patients, glucose concentration was within
the target range (3.9–6.7 mmol/L) 68% of the time over the
10-day postoperative period of the study. During this time, we
recorded 12 ± 6 low glucose events (< 3.9 mmol/L) per pa-
tient, which were more frequent in patients being treated for
DM2 than in those without the disease (14 ± 5 vs. 9 ± 6; p =
0.035). The mean duration of a hypoglycemic event was 245
(165.5–364) min. Table 2 presents the CGM data for patients
with DM2 after either LSG or LRYGB. After LRYGB, pa-
tients with DM2 had a higher incidence of low glucose con-
centration episodes (< 3.9 mmol/L), which lasted significantly
longer than they did in patients with DM2 who had undergone
LSG (p = 0.035 and 0.049, respectively). Mean daily glucose
concentration on day 1 and days 2–3 did not differ between
the groups. Significantly lower glucose concentrations were
measured from fourth day of CGM (third postoperative day)
until the end of the observation period in patients with DM2
that had undergone LRYGB, compared with patients with
DM2 that had undergone LSG. Symptomatic hypoglycemic
events were observed in four patients after LRYGB with
DM2. They required infusions of intravenous glucose due to
altered mental status or symptoms of increased activity of
sympathetic system. Only two patients, both after LSG, did
not suffer from any hypoglycemia. Low glucose concentra-
tions, either symptomatic or asymptomatic, were present both
after LSG and LRYGB respectively in 16 and 14 patients. The
variations in daily glucose concentrations are presented in
Fig. 2.
In Table 3 we show a comparison of CGM data for patients
without DM2 following LSG or LRYGB. There were no sig-
nificant differences in mean glucose concentration over the
whole period, nor in the incidence of low glucose events or
their duration. The variations in glucose concentrations are
presented in Fig. 3.
Table 4 shows comparison of studied parameters of CGM
in all LSG vs. all LRYGB patients. We were able to document
significantly lower mean glucose concentrations in all
LRYGB on days 7–10 of CGM in comparison with patients
after LSG. Additionally, Fig. 4 demonstrates significant in-
crease in mean glucose concentrations from days 2 to 6 of
CGM present after both types of procedures. On days 7–10
of CGM, mean glucose concentrations after LRYGB were
significantly lower than on day 1, which was not observed
in case of patients after LSG.
Discussion
This pilot study is one of the few studies that has been con-
ducted using CGM to compare glucose metabolism during a
significant period (10 days) following LSG and LRYGB. Our
main goal was to investigate changes in glycemic control in
the early postoperative period and to compare daily glucose
fluctuations in patients who underwent LRYGB and LSG. We
included 16 patients with DM2 and 16 in control group.
Patients with DM2 predominantly underwent LRYGB and
were significantly older than in control group. ASA class
was higher in DM2 patients, what was reflected by higher
comorbidity index. Diabetes mellitus was well-controlled on
oral medications, which reflects in preoperative HbA1c and
means of daily glucose concentrations on the day prior to
operations. We recorded metabolic reaction to surgery, which
is reflected by significantly higher glucose concentrations on
the first and second postoperative day after both LSG and
LRYGB, which normalized overtime. Starting from the third
day after surgery, significantly lower glucose concentrations
were measured in patients with DM2 that had undergone
LRYGB, compared with patients with DM2 that had under-
gone LSG. In patients without DM2, there were no significant
differences in mean glucose concentration during the obser-
vation period, or in the incidence or duration of low glucose
events, between those who had undergone LSG and LRYGB.
Table 2 Results of CGM in patients with DM2 after LSG and LRYGB
LSG LRYGB P value
Average glucose concentration overtime, mmol/L (IQR) 5.3 (4.0–8.2) 4.5 (4.3–4.9) 0.127
% of glucose concentration measurements in targeted compartment (70–120 mmol/L); (IQR) 50% (9–88%) 75% (69–80%) 0.513
% of glucose concentration measurements below targeted compartment (70–120 mmol/L); (IQR) 1% (0–5%) 25% (10–30%) 0.127
% of glucose concentration measurements above targeted compartment (70–120 mmol/L); (IQR) 11% (0–91%) 1% (0–5%) 0.264
Low glucose concentration events, n ± SD 5 ± 5.59 11.6 ± 5.36 0.035
Average time of low glucose event, min (IQR) 110 (0–439) 262 (241–511) 0.049
Estimated HbA1c%, % (IQR) 5% (4.1–6.7%) 4.65% (4.05–6.45%) 0.603
Mean daily glucose concentration on day 1, mmol/L ± SD 4.3 ± 0.9 4.4 ± 1.2 0.805
Mean daily glucose concentration on days 2–3, mmol/L ± SD 5.1 ± 0.5 5.0 ± 1.0 0.876
Mean daily glucose concentration on days 4–6, mmol/L ± SD 5.8 ± 2.4 4.2 ± 0.5 0.005
Mean daily glucose concentration on days 7–10, mmol/L ± SD 6.0 ± 1.8 3.0 ± 1.5 < 0.001
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Previously published studies of the changes in glucose
status during the postoperative period after surgical treat-
ment of obesity that used CGM were conducted over a
shorter period and focused only on patients who had un-
dergone gastric bypass or had DM2 [22, 23]. Numerous
publications have demonstrated the clinical benefits of the
CGM system used in this study in various patient popu-
lations. These included pediatric, adolescent, and adult
patients with type 1 and type 2 diabetes, patients with
poor baseline glycemic control, and patients undergoing
bariatric surgery [24–31]. The use of this system is asso-
ciated with an improvement in HbA1c and a reduction in
the risk of hypoglycemia [29]. This is because continuous
subcutaneous glucose measurement provides the most rel-
evant information regarding glucose status of the avail-
able methods [32].
Bariatric surgery improves glycemic control by multiple
weight-dependent and weight-independent mechanisms,
which have their origin in the gastrointestinal system [33].
This study investigated the changes in glucose status for a
relatively short period of 10 days, which did not allow us to
draw conclusions regarding the resolution of DM2 after bar-
iatric surgery. However, previous publications have reported
that shortly after both LRYGB and LSG there is an improve-
ment in glycemic control in patients with DM2. The main
finding of this study was that there are significantly lower
glucose concentrations from the third postoperative day in
patients with DM2 that undergo LRYGB, compared with pa-
tients with DM2 that undergo LSG. This could be explained
by greater incretin release following LRYGB. This finding, if
replicated in a larger-scale, longer-term study, preferably a
randomized controlled trial (RCT), would indicate a need for
Table 3 Results of CGM in patients without DM2 after LSG and LRYGB
LSG LRYGB P value
Average glucose concentration overtime, mmol/L (IQR) 4.5 (4.2–5.2) 4.4 (4.0–4.9) 0.488
% of glucose concentration measurements in targeted compartment (70–120 mmol/L); (IQR) 70.5% (43–77%) 63% (60–66%) 0.329
% of glucose concentration measurements below targeted compartment (70–120 mmol/L); (IQR) 19.5% (9–50%) 31% (22–20%) 0.624
% of glucose concentration measurements above targeted compartment (70–120 mmol/L); (IQR) 7.5% (3–14%) 6% (0–12%) 0.736
Low glucose concentration events, n ± SD 14.8 ± 5.54 12.5 ± 4.04 0.357
Average time of low glucose event, min (IQR) 240.5 (166–289) 207 (165–249) 0.329
Estimated HbA1c%, % (IQR) 4.45% (4.3–4.9%) 4.85% (4.7–5%) 0.084
Mean daily glucose concentration on day 1, mmol/L ± SD 4.2 ± 1.3 3.9 ± 1.2 0.592
Mean daily glucose concentration on days 2–3, mmol/L ± SD 5.3 ± 0.8 4.3 ± 1.6 0.107
Mean daily glucose concentration on days 4–6, mmol/L ± SD 4.2 ± 0.6 4.5 ± 0.7 0.706
Mean daily glucose concentration on days 7–10, mmol/L ± SD 3.9 ± 0.6 4.7 ± 0.8 0.202
Fig. 2 Scope of daily glucose
concentrations in patients with
DM2 after LSG and LRYGB
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an early reduction in the dose of administered DM2
medication.
The prevalence of symptomatic hypoglycemic events have
been reported as 0.1%, based on self-reported episodes or
hospi ta l admiss ions for hypoglycemia [34, 35] .
Nevertheless, another study reported prevalence of 34% bas-
ing on self-reported symptoms consistent with hypoglycemia
[36]. Direct testing, either with oral glucose test or CGM,
showed that it can be present even in 10–70% patients
[37–40]. In case of our study, symptomatic hypoglycemia
(defined as need for intervention due to altered mental status
or severe sympathetic symptoms) was observed in 12.5% of
patients. Asymptomatic hypoglycemic events were recorded
in almost all patients.
In patients without DM2 that had undergone LSG or
LRYGB, we did not show significant differences in mean
glucose concentration over time, or in the incidence or
duration of low glucose events, which is not consistent with
some reports that have documented postoperative hypoglyce-
mia in non-diabetic patients. Following bariatric surgery, he-
patic insulin sensitivity is elevated because of caloric restric-
tion and an increase in β-cell insulin secretion, secondary to
an increase in postprandial GLP-1 secretion, caused by chang-
es in the nutrients entering the distal small intestine [41–43].
Non-diabetic patients are commonly affected by hypoglyce-
mic episodes after the surgical treatment of obesity [39, 44]. A
study by Tharakan et al. demonstrated associations between
higher plasma GLP-1, glucagon, and the hyperinsulinemic
hypoglycemia observed in this situation [45]. Yip et al.
showed that both LRYGB and LSG reduce glycemia and in-
crease glucose tolerance [46], while Kellog et al. proposed
that hyperinsulinemic hypoglycemia results from a severe
form of late dumping syndrome after gastric bypass surgery,
and can be significantly ameliorated through dietary
Table 4 Results of CGM in all patients after LSG and all after LRYGB
LSG LRYGB P value
Average glucose concentration overtime, mmol/L (IQR) 4.7 (4.2–5.3) 4.5 (4–4.9) 0.230
% of glucose concentration measurements in targeted compartment (70–120 mmol/L); (IQR) 67% (43–77%) 69% (60–80%) 0.608
% of glucose concentration measurements below targeted compartment (70–120 mmol/L); (IQR) 9% (6–50%) 25% (10–40%) 0.286
% of glucose concentration measurements above targeted compartment (70–120 mmol/L); (IQR) 8% (3–14%) 1% (0–12%) 0.075
Low glucose concentration events, n ± SD 11.6 ± 7.2 11.9 ± 4.9 0.894
Average time of low glucose event, min (IQR) 196 (110–289) 249 (195–511) 0.254
Estimated HbA1c%, % (IQR) 4.6% (4.3–5%) 4.8% (4.4–5%) 0.551
Mean daily glucose concentration on day 1, mmol/L ± SD 4.2 ± 1.1 4.3 ± 1.2 0.975
Mean daily glucose concentration on days 2–3, mmol/L ± SD 5.3 ± 0.7 4.8 ± 0.9 0.305
Mean daily glucose concentration on days 4–6, mmol/L ± SD 4.8 ± 1.6 4.3 ± 0.6 0.263
Mean daily glucose concentration on days 7–10, mmol/L ± SD 4.6 ± 1.5 3.5 ± 1.4 0.013
Fig. 3 Scope of daily glucose
concentrations in CGM in
patients without DM2 after LSG
and LRYGB
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intervention [47]. Despite including patients with short dura-
tion of DM2 and not on insulin injections, the incretin effect
was stronger in patients without DM2 than in patients with
DM2. This was reflected by higher prevalence of low glucose
concentrations overtime (19.5 and 31% in no-DM2 subgroups
vs. 1 and 25% in DM2 subgroups) and low glucose events
(14.8 and 12.5 in non-DM2 vs. 5 and 11.6 in DM2 sub-
groups). However we did not find research investigating that
phenomenon. Degeneration of pancreatic β-cells is
pathophysiologically related to onset of DM2 along with pe-
ripheral insulin resistance. We can only hypothesize that in
patients with DM2, the degeneration of β-cells is weakening
incretin effect.
We observed a rapid elevation in interstitial glucose con-
centration after surgery, which was similar between patients
with and without DM2. This increase was larger in the LSG
group, although the difference between the type of procedure
was not statistically significant. Patients regained their preop-
erat ive glucose concentrat ion af ter ~ 7–10 days.
Gastrointestinal surgery is associated with a complexmetabol-
ic response, as well as surgical stress inducing endocrine and
inflammatory responses. During the period following a gas-
trointestinal procedure, patients experience elevations in cor-
tisol, growth hormone, glucagon, catecholamine, and pro-
inflammatory cytokines (interleukins, IL-1 and IL-6), follow-
ed by increases in anti-inflammatory cytokines [48, 49]. Prior
to conducting surgery on patients with DM2, preoperative
assessment and planning is required to establish a suitable
treatment regimen that will minimize the risk of complications
[50, 51]. Previous studies, in addition to our data, have shown
that the period following a surgical procedure is often charac-
terized by hyperglycemia, which results in a greater incidence
of complications and higher costs connected to hospitalization
[52–54].
Despite a limited number of patients, we were able to dem-
onstrate a significant difference in the mean daily glucose
concentrations on days 4–6 and 7–10 in patients with DM2
after LRYGB in comparison to patients with DM2 after LSG.
Additionally, we found significantly more frequent low glu-
cose concentration events and a longer time of those events in
the first subgroup. We suggest that with larger study popula-
tion there would also likely be a significant difference in the
frequency of glucose concentrations below targeted compart-
ment (LRYGB vs. LSG, 25 and 1%) and above the targeted
compartment (LRYGB vs. LSG, 1 and 11%). In that situation,
LRYGB would be a more curative procedure for DM2 in the
early postoperative period. Supportive observation is that
when analyzing all LSG vs. all LRYGB patients, we found
significant difference in mean glucose concentrations on the
days 7–10, lower in the LRYGB subgroup. Perioperative
shock reaction was an increase in mean glucose concentra-
tions from days 2 to 6 of CGM present after both types of
procedures, as mentioned previously. On days 7–10 of CGM,
mean glucose concentrations after LRYGB were significantly
lower than on day 1, what was not observed in case of patients
after LSG.
We can speculate that more significant findings and corre-
lations would have been identified if the study had been con-
ducted on a larger group of patients. However, an appropriate
sample size for a more comprehensive future study can be
calculated using the data presented in this publication.
Unfortunately, for the moment, the differences in glucose sta-
tus in the period following LSG and LRYGB remains to be
conclusively established.
Fig. 4 Scope of daily glucose
concentrations in CGM in all
patients after LSG vs. all LRYGB
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Limitations
This study had several limitations. First, the sample size was
small and the duration of observation was short, because of
funding restrictions. Therefore, we decided to conduct a pilot
study, which would validate methodology for a more compre-
hensive follow-up study, preferably an RCT. A potential
source of bias associated with this study is an error in glucose
measurement, as described by the CGM device manufacturer,
as well as patient error, although a precise description of the
device, including data on measurement error, has been added
to the manuscript, and patients were thoroughly instructed on
the use of the CGM device prior to their enrolment in the
study. Further studies of larger groups of patients, categorized
according to the clinical severity of their DM2, and conducted
over a longer period, are required.
Conclusions
In conclusion, significantly lower glucose concentration is
present from the third postoperative day in patients with
DM2 that undergo LRYGB, than in those that undergo LSG.
However, patients with DM2 that undergo LRYGB are more
likely to experience low glucose episodes and these are likely
to be longer, than in those that undergo LSG. This indicates
the dose of anti-diabetic medication should be reduced in the
former group, even before significant weight reduction occurs.
CGM permits a very effective demonstration of the perioper-
ative metabolic reaction to bariatric procedures.
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